Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06162377 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

StatusRecruiting
PhasePhase 4
Started2024-01-10
View on ClinicalTrials.gov ↗

Amendment history

2026-06-09
Study Status v7
Re-verified, no change to tracked fields
2025-12-12
Study Status v6
Primary completion date2025-12-31→2026-12-31
Completion date2025-12-31→2026-12-31
2025-08-12
Study Status v5
Re-verified, no change to tracked fields
2025-02-10
Study Status v4
Primary completion date2026-06-30→2025-12-31
Completion date2026-06-30→2025-12-31
2025-01-23
Study Status v3
Re-verified, no change to tracked fields
Show 2 earlier versions
2024-07-18
Study Status v2
Primary completion date2024-06-30→2026-06-30
Completion date2024-06-30→2026-06-30
2024-01-10
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-04-30→confirmed 2024-01-10
Study sitesdetails revised at 1 of 1 site
2023-11-30
Original filing
To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.
Trial Details
NCT Number NCT06162377
Lead Sponsor M.D. Anderson Cancer Center
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 25 participants
Start Date 2024-01-10
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-10